

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2003279835 B2**

(54) Title
Methods of administering FGF18

(51) International Patent Classification(s)
A61K 38/18 (2006.01) **A61K 47/36** (2006.01)
A61K 9/00 (2006.01) **C07C 51/38** (2006.01)
A61K 45/06 (2006.01) **C07C 67/343** (2006.01)

(21) Application No: **2003279835** (22) Date of Filing: **2003.10.07**

(87) WIPO No: **WO04/032849**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/416,670	2002.10.07	US

(43) Publication Date: **2004.05.04**

(43) Publication Journal Date: **2004.06.03**

(44) Accepted Journal Date: **2009.09.10**

(71) Applicant(s)
ZymoGenetics, Inc.

(72) Inventor(s)
Ellsworth, Jeff L.

(74) Agent / Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market Street, Sydney, NSW, 2000

(56) Related Art
AU 2002319888

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032849 A3

(51) International Patent Classification⁷: **A61K 31/728**,
31/717, 38/18, C07K 14/50

(21) International Application Number:
PCT/US2003/031550

(22) International Filing Date: 7 October 2003 (07.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/416,670 7 October 2002 (07.10.2002) US

(71) Applicant: **ZYMOGENETICS, INC.** [US/US]; 1201
Eastlake Avenue East, Seattle, Wa 98102 (US).

(72) Inventor: **ELLSWORTH, Jeff, L.**; 4225 51st Avenue
South, Seattle, WA 98118 (US).

(74) Agent: **JOHNSON, Michelle, L.**; ZymoGenetics, Inc.,
1201 Eastlake Ave E, Seattle, WA 98102 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
30 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/032849 A3

(54) Title: METHODS OF ADMINISTERING FGF18

(57) Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.

Description

5

METHODS FOR ADMINISTERING FGF18

BACKGROUND OF THE INVENTION

The fibroblast growth factor (FGF) family consists of at least twenty three distinct members (Basilico et al., Adv. Cancer Res. 59:115-165, 1992 and Fernig et al., Prog. Growth Factor Res. 5(4):353-377, 1994) which generally act as mitogens for a broad spectrum of cell types. FGF18 was identified as a member of the FGF family which was most closely related to FGF8 and FGF17. Activities associated with FGF18 included stimulation of mesenchymal lineage cells, in particular cardiac myocytes, osteoblasts and chondrocytes (U.S. Patent No. 6,352,971). FGF18 binds and activates FGFR4 and the "IIIc" splice variants of FGFR3 and FGFR2. It has been shown that FGFR3 plays a role in bone growth. Mice made homozygous null for the FGFR3 (-/-) resulted in postnatal skeletal abnormalities (Colvin et al., Nature Genet. 12:309-397, 1996 and Deng et al., Cell 84:911-921, 1996). The mutant phenotype suggests that in normal mice, FGFR-3 plays a role in regulation of chondrocyte cell division in the growth plate region of the bone (Goldfarb, Cytokine and Growth Factor Rev. 7(4):311-325, 1996). FGF receptor mutations are also found in human chondrodysplasia and craniosynostosis syndromes (Ornitz and Marie, Genes and Development 16: 1446-1465, 2002).

Bone remodeling is the dynamic process by which tissue mass and skeletal architecture are maintained. The process is a balance between bone resorption and bone formation, with two cell types thought to be the major players. These cells are the osteoblast and osteoclast. Osteoblasts synthesize and deposit matrix to become new bone. The activities of osteoblasts and osteoclasts are regulated by many factors, systemic and local, including growth factors.

When bone resorption exceeds bone formation, a net loss in bone results, and the propensity for fractures is increased. Decreased bone formation is associated with aging and certain pathological states. In the U.S. alone, there are approximately 1.5 million fractures annually that are attributed to osteoporosis. The impact of these fractures on the quality of the patient's life is immense. Associated costs to the health care system in the U.S. are estimated to be \$5-\$10 billion annually, excluding long-term care costs.

Other therapeutic applications for growth factors influencing bone remodeling include, for example, the treatment of injuries which require the proliferation of osteoblasts to heal, such as fractures, as well as stimulation of mesenchymal cell proliferation and the synthesis of intramembraneous bone which have
5 been indicated as aspects of fracture repair (Joyce et al. 36th Annual Meeting, Orthopaedic Research Society, February 5-8, 1990. New Orleans, LA).

Replacement of damaged articular cartilage caused either by injury or disease is a major challenge for physicians, and available treatments are considered unpredictable and effective for only a limited time. Virtually all the currently available
10 treatments for cartilage damage focus on relief of pain, with little or no emphasis on regeneration of damaged tissues. Therefore, the majority of younger patients either do not seek treatment or are counseled to postpone treatment for long as possible. When treatment is required, the standard procedure is a total joint replacement or microfracture, a procedure that involves penetration of the subchondral bone to
15 stimulate fibrocartilage deposition by chondrocytes. While deposition of fibrocartilage is not a functional equivalent of articular cartilage, it is at the present the best available treatment because there has been little success in replacing articular cartilage. Two approaches to stimulating deposition of articular cartilage that are being investigated are: stimulating chondrocyte activity *in vivo* and *ex vivo* expansion of chondrocytes and
20 their progenitors for transplantation (Jackson et al., Arthroscopy: The J. of Arthroscopic and Related Surg. 12:732-738, 1996). In addition, regeneration or repair of elastic cartilage is valuable for treating injuries and defects to ear and nose. Any growth factor with specificity for chondrocytes lineage cells that stimulates those cells to grow, differentiate or induce cartilage production would be valuable for maintaining, repairing
25 or replacing articular cartilage.

Administration of proteins generally requires a formulation that prolongs the half-life or biological activity of the active protein by increasing the resistance to proteolytic degradation or aggregation. Delivery of a protein therapeutic composition can also be difficult when the site for therapeutic action is preferably
30 limited to a specific location in the body. The present invention provides formulations of FGF18 that will be easier to administer and more effective, and other uses that should be apparent to those skilled in the art from the teachings herein.

DETAILED DESCRIPTION OF THE INVENTION

35 Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

The term "hyaluronic acid" are used herein to include derivatives of hyaluronic acid that include esters of hyaluronic acid, salts of hyaluronic acid and also includes the term hyaluronan. The designation also includes both low and high molecular weight forms of hyaluronans and crosslinked hyaluronans or hylans. Examples of such hyaluronans are Synvisc® (Genzyme Corp. Cambridge, MA), ORTHOVISC® (Anika Therapeutics, Woburn, MA), and HYALGAN® (Sanofi-Synthelabo Inc., Malvern, PA)

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of

other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with
5 which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

An "isolated" polypeptide or protein is a polypeptide or protein that is
10 found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term "isolated" does not exclude
15 the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

20 A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides
25 ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length
30 and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10
35 amino acid residues are commonly referred to as "peptides".

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

5 A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures;
10 substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-peptide structure comprising
15 an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand
20 interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g.,
25 PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in
30 which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated
35 value of X will be understood to be accurate to $\pm 10\%$.

All references cited herein are incorporated by reference in their entirety.

The present invention is based in part on the discovery that when compositions of FGF18 polypeptides or proteins plus a negatively charged carrier, such as hyaluronic acid, are administered to a synovial joint, the stimulatory effects of the FGF18 are enhanced. Therefore, the present invention is directed to compositions of FGF18 polypeptides or proteins plus negatively charged carriers, in particular hyaluronic acid for stimulating the proliferation of mesenchymal cells, particularly chondrocytes. The compositions are administered intraarticularly to a joint, containing synovial fluid.

The nucleotide sequence of the FGF18 cDNA is described in SEQ ID NO. 1, and its deduced amino acid sequence is described in SEQ ID NO. 2. FGF18 was originally designated zFGF5, and is fully described in commonly assigned U.S. Patents 6,352,971 and 5,989,866, both incorporated herein by reference. Analysis of the cDNA encoding a FGF18 polypeptide (SEQ ID NO: 1) revealed an open reading frame encoding 207 amino acids (SEQ ID NO: 2) comprising a mature polypeptide of 180 amino acids (residue 28 to residue 207 of SEQ ID NO: 2).

The mouse FGF18 polynucleotide sequence as shown in SEQ ID NO: 3 and corresponding amino acid sequence as shown in SEQ ID NO: 4 were found to have a high degree of homology to that of the human ortholog. At the amino acid level, the mouse and human polypeptides are approximately 98% identical, with three amino acid changes. Those skilled in the art will recognize that the sequences disclosed in SEQ ID NO: 1 or SEQ ID NO: 3 and SEQ ID NO: 2 and SEQ ID NO: 4 represent a single allele of the human and mouse FGF18 gene and polypeptide, respectively, and that allelic variation and alternative splicing are expected to occur.

Members of the FGF family are characterized by heparin binding domains. A putative heparin-binding domain for FGF18 has been identified in the region of amino acid residue 148 (Gly) to amino acid residue 169 (Gln) of SEQ ID NO: 2 and SEQ ID NO: 4. It is postulated that receptor-mediated signaling is initiated upon binding of FGF ligand complexed with cell-surface heparin sulfate proteoglycans. Many FGF family members can be placed into one of two related families on the basis of their structures and functions. aFGF and bFGF consist of three exons separated by two introns of variable length. FGF-8 consists of five exons, the first three of which correspond to the first exon of aFGF and bFGF. All the known FGF family members are spliced to form single polypeptides.

Analysis of the ligand-receptor complex of FGF18 has demonstrated that FGF18 has specificity for FGFR4 and the "IIIc" splice variants of FGFR3 and FGFR2.

FGFR3-IIIc and FGFR2-IIIc have been identified within chondrocytes of cartilage tissue, and in particular, both receptors have been found within human articular cartilage. FGFR3 and FGFR2 have been found in the growth plate of mammals and play important roles in the formation of endochondral and intramembranous bone. In particular, FGFR2 and FGFR3 play important roles in developing endochondral and intramembranous bone, FGFR2 is first expressed in condensing mesenchyme and FGFR3 expression is initiated as chondrocytes differentiate and proliferate. In developing cranial bones, FGFR3 is found in the dura mater and periosteum, whereas FGFR2 is expressed in osteoprogenitor cells at the osteogenic front separating the sutures. FGFR2 is also expressed in trabecular bone. (Ornitz and Marie, *ibid.*, 2002) Previously, it has been shown that FGF18 is a proliferative agent for chondrocytes and osteoblasts, depending upon both the differentiated state of these cell types and the mode of administration. (See, U.S. Patents 6,352,971 and 5,989,866; Ellsworth et al. Osteoarthritis and Cartilage, 10:308-320, 2002; Shimoaka et al., J. Bio.Chem. 277 (9) 7493-500, 2002).

Osteoarthritis causes pain in the joints, is believed to be caused by a deficiency in the production of extracellular matrix including sulfated proteoglycans, hyaluronic acid (HA) and type II collagen. HA is natural high viscosity mucopolysaccharide with alternating, (1-3) glucuronic and, (1-4) glucosaminidic bonds. It is found in the umbilical cord, in vitreous humor, and synovial fluids. For use in the treatment methods and compositions of the present invention, any source of HA is appropriate, however, recombinantly-produced HA (i.e., protein produced in bacterial, yeast, or mammalian cell culture) may be preferred over isolation from animal or human tissue sources in order to insure purity of the composition. In the connective tissue HA functions as binding and protective agent. HA fractions and salts of HA have been used for treatment of damaged bone joints and osteoarthritis. (See, U.S. Patent 5,925,626; U.S. Patent 5,631,241 and EP 0,939,086.) HA is also used in viscosupplementation and as an aid in ophthalmic surgery.

HA has been used as a component for therapeutic treatment of a variety of conditions, both using the HA as the primary therapeutic and as a component of a therapeutic composition useful for treatment. In experiments done by others, HA scaffolds were used to implant autologous chondrocytes into patients' knees, with data showing that symptomatic and functional improvements results. Raynauld et al. (Osteoarthritis and Cartilage, 10(7):506-517, 2002) describe results using an HA formulation in conjunction with appropriate care in which clinical effectiveness for primary and secondary outcomes were improved over appropriate care alone.

Generally, primary outcomes can be measured as change in the Western Ontario and McMaster (WOMAC) osteoarthritis index, which is a measurement of pain. Secondary outcomes measures will include functional disability and self-reported quality of life. If the therapeutic outcome includes a disease modifying agent, then joint morphology is a primary outcome variable, as well. (Hochberg et al., J. of Rheumatolog. 24(4):792-794, 1997).

U.S. Patent 4,636,524 discloses cross-linked gels of HA, alone and mixed with other hydrophilic polymers and containing various substances or covalently bonded low molecular weight substances and processes for preparing them. These products are useful in numerous applications including cosmetic formulations and as drug delivery systems. HA is known to be a biologically tolerable polymer in the sense that it does not cause any immune or other kind of response when introduced into a human body, the cross-linked HA gels can be used for various medical applications. The cross-linked gels modified with other polymers or low molecular weight substances can be used as drug delivery devices.

Canadian Letters Patent 1,240,929 teaches the combination of chondroitin sulfate compound and a hyaluronate to protect both human and animal cell layers and tissue subject to exposure to trauma.

U.S. Patent 4,851,521 and European Patent Application 0,265,116, both describe HA fractions and cross-linked esters of HA. U.S. Patent 4,851,521 describes esters of HA incorporated into pharmaceutical preparations as the active ingredient and as vehicles for ophthalmological medicines for topical use and in suppositories for a systemic effect due to the effect of transcutaneous absorption, such as in suppositories.

U.S. Patent Nos. 6,221,854 and 5,942,499 C1 (Reexam 4806) describe the use of HA and basic FGF (FGF-2) for the treatment of bone. The patent teaches an injectable mixture that is administered into an orthotopic or intraosseous site of desired bone growth.

In contrast, the FGF18 polypeptide and HA compositions of the present invention provide a method for stimulating the proliferation of chondrocytes, in particular differentiated chondrocytes, capable of inducing specialized cell functions, normally associated with terminally differentiated cells. When a composition of FGF18 and HA was administered locally to articular cartilage, proliferation of the cells and concomitant synthesis of glycosaminoglycans was increased beyond the results seen either with FGF18 alone or HA alone. These results indicate that compositions of FGF18 polypeptides and HA can play a therapeutic role in maintaining or repairing

cartilaginous tissue, such as joints damaged by osteoarthritis, rheumatoid arthritis or traumatic injury.

FGF18 has been shown to increase cartilage deposition both *in vivo* and *in vitro*. Generation of hyaline cartilage, elastic cartilage, and fibrocartilage are
5 valuable both as a therapeutic and as component for biological matrices. FGF18 and HA compositions will be useful in treating articular cartilage defects in synovial joints that are due to age-related superficial fibrillation, cartilage degeneration due to osteoarthritis, and focal chondral and osteochondral defects due to injury or disease. FGF18 and HA compositions will also be useful for treating joint disease caused by
10 osteochondritis dissecans and degenerative joint disease. In the field of reconstructive and plastic surgery, FGF18 and HA compositions will be useful for autogenous or allogenic cartilage expansion and transfer for reconstruction of extensive tissue defects. Expansions of cells and induction of elastic cartilage production will be useful for generation and repair of ear and nose tissue.

15 FGF18 compositions can be applied by direct injection into the synovial fluid of the joint or directly into the defect, either alone or complexed with a suitable carrier for extended release of protein. However, when FGF18 polypeptide and HA were delivered directly to the synovial joint, the effects of the compositions to stimulate chondrocytes proliferation exceeded that of FGF18 polypeptide or HA alone.

20 FGF18 can also be used to expand chondrocyte populations in culture for autogenous or allogenic chondrocyte transplantation and then administered with concurrent treatment consisting of administration of FGF18 polypeptide and HA compositions. In these procedures, for example, chondrocytes can be harvested arthroscopically from an uninjured minor load-bearing area of the damaged joint, and
25 can be cultured in the presence of FGF18 compositions to increase the number of cells prior to transplantation. The expanded cultures will then be admixed with FGF18 polypeptide and HA compositions, and placed in the joint space or directly into the defect. FGF18 and HA compositions can be used in combination with periosteal or perichondrial grafts that contain cells that can form cartilage and/or help to hold the
30 transplanted chondrocytes or their precursor cells in place. FGF18 and HA compositions can be used to repair cartilage damage in conjunction with lavage of the joint, stimulation of bone marrow, abrasion arthroplasty, subchondral drilling, or microfracture of the subchondral bone. Additionally, after the growth of cartilage due to the administration of the FGF18 and HA composition, additional surgical treatment
35 may be necessary to suitably contour the newly formed cartilage surface.

In a first aspect of the invention there is provided a composition for intraarticular delivery of chondrogenic polypeptides comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.

5 In a second aspect of the invention there is provided a method for increasing chondrocyte proliferation in a joint of a mammal in need thereof comprising the step of administering into a synovial cavity a composition comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.

10 In a third aspect of the invention there is provided a method of treating osteoarthritis in a mammal comprising the steps of administering into a synovial cavity a composition comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.

In a fourth aspect of the invention there is provided the use of a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid for the manufacture of a medicament for the treatment of osteoarthritis in a mammal.

15 The compositions of the present invention provide a method for stimulating chondrocyte proliferation and cartilage production in cartilagenous tissues that have been damaged due to traumatic injury or chondropathy. Of particular importance for treatment are tissues that exhibit articulated surfaces, such as, spine, shoulder, elbow, wrist, joints of the fingers, hip, knee, ankle, and the joints of the feet. Examples of diseases that may benefit from treatment include osteoarthritis, rheumatoid arthritis, other autoimmune diseases, or osteochondritis dessicans. In addition, cartilage malformation is often seen in forms of dwarfism in humans suggesting that FGF18 would be useful in these patients.

20 FGF18 and HA compositions can be applied by direct injection into the synovial space of the joint, into nearby tissues, or directly into a cartilage defect in combination with a carrier that exhibits a negative charge under physiological conditions. Since FGF18 has an isoelectric point of >9.0 , at physiological pH FGF18 exhibits a net positive charge. Thus carrier molecules with an abundance of negative charge may bind FGF18 and enhance its activity. Such carriers include low and high molecular weight hyaluronans, sulfated proteoglycans, B-cyclodextrin tetradecasulphate, hydroxyapatite, alginate microspheres, chitosans, and methylcellulose.

30 For pharmaceutical use, the compositions of the present invention are formulated for intraarticular administration according to conventional methods. The dosage regiment will be determined using various patient variables (e.g., weight, age, sex), as well as clinical presentation (e.g., extent of injury, site of injury, etc.) In general, pharmaceutical

formulations will include a FGF18 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, extend half-life, etc.

5 The FGF18 and HA may be administered separately or in combination as a single composition. Thus, the formulations may be provided as a single formulation or as a multicomponent kit. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference. Determination of dose

10 is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years.

In other embodiments, a pharmaceutical FGF18 and HA composition will comprise a formulation for timed-release of the protein. Time-release formulations generally include a monolithic delivery device comprising biocompatible solutions, gels, pastes, and putties in a matrix, in which the composition is entrapped or dissolved.

5 Release from such a timed-release composition occurs by diffusion through the matrix and/or erosion of the matrix. A reservoir system, where the pharmaceutical composition diffuses through a membrane, may also be used.

Although administration of FGF18 and HA, in a pharmaceutically acceptable admixture, is sufficient to provide the delivery of the chondrogenic peptides

10 of the present method, there may be clinical situations where additional drugs are combined in the admixture. Examples of other drugs which may be clinically indicated include anti-inflammatory drugs such as nonspecific and specific cyclooxygenase-2 inhibitors, non-steroidal and steroidal anti-inflammatory drugs. Some of the nonspecific COX inhibitors that could be used in the present invention include salicylic

15 acid and derivatives, such as aspirin or sulfasalazine, para-aminophenol derivatives, such as acetaminophen, indole and indene acetic acids, such as indomethacin or sulindac, arylpropionic acids, such as ibuprofen, naproxen, or oxaprozin, anthranilic acids, such as mefenamic acid, enolic acids including oxicams, or alkanones, such as nabumentone. Specific COX-2 inhibitors would be diaryl-substituted fuanones

20 (Refecoxib), diaryl-substituted pyrazoles (Celecoxib), indole acetic acids (Etodolac) and sulfonamides (Nimesulide). Additionally, steroids, such as dexamethazone, prednisone, triamcinolone, or methylprednisone, are among the drugs that could be used. Other types of drugs suitable for the present invention would be inhibitors of the tumor necrosis factor family, such as Enbrel or TACI-Ig, IL-1 antagonists such as

25 Kinaret, antagonists of IL-18 and IL-15, and immunosuppressive drugs such as cyclosporine. In addition, FGF18 may be administered with inhibitors of the CC (MCP-1, RANTES, MIP-1alpha, and MIP-1beta) and CXC (IL-8 and GRO-alpha) chemokine family.

The invention is further illustrated by the following non-limiting examples.

30

Example 1
Intraarticular injection of FGF18

FGF18 was lyophilized and reconstituted at the appropriate

35 concentration in either PBS or 0.5% hyaluronan (0.2 um sterile filtered). A single dose of FGF18, vehicle (PBS), hyaluronan or the appropriate combination of FGF18 dissolved in either PBS or 0.5% hyaluronan, contained in a final volume of 5 µl was

injected into the intraarticular space of the left stifle (knee) of 10 week old female c57/B16 mice. There were seven animals per group. All dosing was performed under isoflurane anesthesia and 100 μ l of buprenorphine was administered upon recovery for analgesia. The animals were sacrificed 2 weeks after dosing and tissues were taken for
 5 routine histology.

The following dose groups were used:

Group	treatment
1	no treatment
10 2	PBS
3	5 μ g FGF18 in PBS
4	0.5 μ g FGF18 in PBS
5	0.05 μ g FGF18 in PBS
6	hyaluronan 0.5%
15 7	hyaluronan 0.5% + 5.0 μ g FGF18
8	hyaluronan 0.5% + 0.5 μ g FGF18
9	hyaluronan 0.5% + 0.05 μ g FGF18
10	sham injection

20 A dose-dependent increase in cartilage formation was observed following two weeks after injection of FGF18 contained in 0.5% hyaluronan. The effective doses were 0.5 and 5 μ g FGF18. Definitive evidence of chondrocyte proliferation was seen in 7/7 animals treated with 5.0 μ g FGF18 in 0.5% hyaluronan and in 3/7 mice treated with 0.5 μ g FGF18 in 0.5% hyaluronan. The increase in
 25 cartilage formation was confined to the margins of the joint in the region of the perichondrium, and did not appear to include the articular surface. Little or no chondrocyte proliferation was seen in any of the other groups. Importantly, neither PBS nor hyaluronan alone had any apparent effects on chondrocyte proliferation. There were no apparent effects on the cartilage proliferation when FGF18 was injected in the
 30 absence of carrier. These observations, combined with those made previously, suggests that the progenitor cells in the perichondrium are a primary target for FGF18. The lack of effect on the articular chondrocytes may be due to the failure of the protein to penetrate the intact articular surface because FGF18 will stimulate the growth and proteoglycan synthesis of primary human and porcine articular chondrocytes *in vitro*.

35 In addition, FGF18 induced closure and mineralization of the growth plate both in the presence and absence of hyaluronan: closure was seen in 2/4 mice treated with 5.0 μ g FGF18 in PBS, 2/6 mice treated with 0.5 μ g FGF18 in PBS, and 1/7 animals treated with 0.05 μ g FGF18 in PBS. This effect was more pronounced in the presence of hyaluronan with closure seen in 7/7 mice treated with 5.0 μ g FGF18 in

0.5% hyaluronan and in 5/7 animals treated with 0.5 μ g FGF18 in 0.5% hyaluronan. These data reinforce the conclusion that hyaluronan enhances the activity of FGF18.

Inflammation was minimal and only observed at the highest doses of FGF18 in combination with hyaluronan. No cartilage degradation was observed, an
5 important point since bFGF has been reported to have both anabolic and catabolic effects on cartilage.

Lastly, no significant systemic effects of FGF18 were observed in animals that received 5 μ g FGF18 with hyaluronan, either at distant cartilage sites or other tissues. However, some focal closures of the epiphysis were observed in one
10 animal that received HA alone and one animal that received 5 gr FGF18 alone. The significance of these observations is not clear at this time.

Example 2

Treatment of Osteoarthritis Model

15

To evaluate whether FGF18 could generate chondral tissue and reverse cartilage degeneration in a setting of osteoarthritis (OA), OA was induced by creating a meniscal tear in the knee joint of rats. In this model, damage to the meniscus induces progressive cartilage degeneration and osteophyte formation that mimic the changes
20 that occur in spontaneous osteoarthritis.

FGF18 was dissolved in a hyaluronan carrier and was applied to the operated knee by intra-articular injection. The repair of cartilage degeneration was evaluated 3 weeks later. The medial collateral ligament of each rat (n=10 rats per group) was transected and the medial meniscus was cut through the full thickness to
25 simulate a complete tear. Three weeks after surgery, rats received intra-articular injections of either vehicle (0.5% hyaluronan) or vehicle containing E. coli-derived recombinant human FGF18 (0.1, 1.0, or 5.0 ug) twice per week for three weeks. Four days after the last injection, the knee joints were harvested, collected into buffered formalin, decalcified, and embedded in paraffin for histology. Frontal sections of the
30 knee joints were stained with toluidine blue to assess formation of chondral tissue. An image of the tibial plateau of each knee was captured using an Optimas image analysis system. Multiple sections of the right knee were analyzed microscopically and scored subjectively for cartilage degeneration (chondrocyte/matrix loss and fibrillation) and chondrocyte formation. Strict attention to zones (outside, middle, and inside thirds of the medial tibial plateau) was adhered to and summed to reflect total severity of tibial
35 degeneration. Micrometer measurements of the total extent of the tibial plateau

affected by degeneration, width of tibial lesions that extended >50% of cartilage thickness (Tibial Cartilage Degeneration Width), lesion depth (Depth Ratio), thickness of the medial tibial cartilage to the tidemark, and chondrocyte size and number were assessed. Statistical analysis of histopathologic parameters was done by comparing
5 group means using the two-tailed Student's t-test or by analysis of variance. All injections and scoring were performed by investigators blinded to the treatment groups.

In this rat OA model, the degeneration of cartilage is most severe on the outer two-thirds of the tibial plateau and reaches maximal levels at 3 weeks following the meniscal damage. FGF18 was administered from 3 to 6 weeks following surgery to
10 determine if it could induce repair of the damaged cartilage. Analysis indicated that FGF18 induced a dose-dependent increase in cartilage hypertrophy and overgrowth of new cartilage around the damaged areas as well as normal cartilage in the lateral compartment. Specifically, the highest dose of FGF18 (5 μ g) resulted in a 57% decrease ($p < 0.05$) in cartilage degeneration scores for the outer 1/3 of the tibial plateau
15 (Table 1), a 57% reduction ($p < 0.05$) in the width of significant tibial cartilage degeneration (Table 2), and a 46% decrease ($p < 0.05$) in depth ratio for any matrix change (Table 3) as a result of filling of the cartilage defects with repair tissue. In addition, FGF18 produced dose-dependent increases in medial tibial cartilage thickness, from 243 ± 21 to 319 ± 77 μ m (Table 4) in rats treated with vehicle or 5.0 μ g of
20 FGF18, respectively.

The morphology of the repair tissue ranged from fibrous with proteoglycan deposition to fibrocartilage. Repair tissue appeared to originate from the marginal zone areas and extended across the degraded and sometimes intact surfaces. In nearly all areas, repair tissue appeared to integrate well with the margins of the
25 remaining normal cartilage. Although the morphology of the repair tissue was different from hyaline cartilage, it appeared to effectively fill the defect and there were virtually no degenerative changes. In contrast to the FGF18-treated animals, rats treated with vehicle alone showed no signs of cartilage repair except in rare cases where erosion of the subchondral bone permitted influx of bone marrow stem cells. In addition to
30 FGF18-mediated chondrogenesis, other changes were noted in the FGF18-treated joints. For example, the medial tibia chondrocyte measurement at the 1 or 5 μ g doses of FGF18 was increased 50% (Table 5).

These data demonstrate that local delivery of FGF18 in a hyaluronan carrier can increase cartilage formation and can reduce cartilage degeneration scores in
35 a rat model of osteoarthritis.

Table 1. FGF18 reduced the medial tibia cartilage degeneration scores.

Treatment Group	Degeneration Score ¹	Number of rats
5 HA alone	3.23 ± 0.34	10
HA+0.1 ug FGF18	2.57 ± 0.39	10
10 HA+1.0 ug FGF18	1.93 ± 0.24	10
HA+5.0 ug FGF18	1.4* ± 0.18	10

¹Mean ± SE. Differences significant, *p=0.0008 by ANOVA.

15

Table 2. FGF18 reduced the size of large cartilage lesions in the medial tibia plateau.

Treatment Group	Significant Tibial Cartilage Degeneration Width (um) ¹	Number of Rats
20 HA alone	576.6 ± 100.4	10
25 HA+0.1 ug FGF18	476.6 ± 95.6	10
HA+1.0 ug FGF18	416.8 ± 87.9	10
HA+5.0 ug FGF18	246.6* ± 50	10

30 ¹Mean ± SE. Differences significant, *p=0.015 by Student's t-test; p=0.067 by ANOVA.

Table 3. FGF18 reduced the depth of cartilage lesions in the medial tibia plateau.

35

Treatment Group	Depth ratio for any matrix change ¹	Number of rats
HA alone	0.45 ± 0.05	10
40 HA+0.1ug FGF18	0.36 ± 0.04	10
HA+1.0 ug FGF18	0.34 ± 0.04	10
45 HA+5.0 ug FGF18	0.24* ± 0.26	10

¹Mean ± SD. Differences significant,*p=0.012 by ANOVA.

Table 4. FGF18 increased the medial tibia cartilage thickness in rats with meniscal tear-induced osteoarthritis.

5	Treatment Group	Cartilage thickness ¹ (um)	Number of rats
	HA alone	243.8 ± 6.7	10
10	HA+0.1 ug FGF18	249.2 ± 5.3	10
	HA+1.0 ug FGF18	276.9 ± 13.5	10
	HA+5.0 ug FGF18	319.1* ± 24.4	10

15 ¹Mean ± SE. Differences significant, p<0.05 by ANOVA.

Table 5. FGF18 increased the size of medial tibia chondrocytes.

20	Treatment Group	Chondrocyte size ¹ (um)	Number of rats
	HA alone	602.4 ± 49.1	10
25	HA+0.1ug FGF18	579.0 ± 34.8	10
	HA+1.0ug FGF18	874.9 ± 120.9	10
	HA+5.0ug FGF18	913.3 ± 51.9	10

30 ¹Mean ± SD. Differences significant, p<0.0005 by ANOVA.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various
 35 modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

The claims defining the invention are as follows:

1. A composition for intraarticular delivery of chondrogenic polypeptides comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.
- 5 2. The composition of claim 1 further comprising a negatively charged carrier.
3. The composition of claim 2 wherein said carrier is selected from the group consisting of low molecular weight hyaluronans, high molecular weight hyaluronans, sulfated proteoglycans, B-cyclodextrin tetradecasulphate, hydroxyapatite, alginate microspheres, chitosans, and methylcellulose.
- 10 4. The composition of claim 1 wherein said composition is a time-release formulation.
5. The composition of claim 4 wherein said time-release formulation comprises a matrix selected from the group consisting of a solution, a gel, a paste, or a putty.
6. The composition of claim 4 wherein said time-release formulation comprises
15 a reservoir system.
7. The composition of claim 1 further comprising chondrocytes wherein said chondrocytes have been cultured in the presence of FGF18 prior to intraarticular administration.
8. The composition of claim 1 further comprising an anti-inflammatory drug.
- 20 9. A method for increasing chondrocyte proliferation in a joint of a mammal in need thereof comprising the step of administering into a synovial cavity a composition comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.
10. A method of treating osteoarthritis in a mammal comprising the steps of
25 administering into a synovial cavity a composition comprising a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid.
11. The method of claim 9 or 10 wherein said administration comprises injection.
12. The method of claim 9 or 10 wherein said administration comprises surgical
implantation.
- 30 13. The method of claim 9 or 10 wherein said admixture further comprises a negatively-charged carrier selected from the group consisting of low molecular weight hyaluronans, high molecular weight hyaluronans, sulfated proteoglycans, B-cyclodextrin tetradecasulphate, hydroxyapatite, alginate microspheres, chitosans, and methylcellulose.

14. The method of claim 9 or 10 where said admixture is a time-release formulation.

15. The method of claim 14 wherein said time-release formulation comprises a matrix selected from the group consisting of a solution, a gel, a paste, or a putty.

5 16. The method of claim 14 wherein said time-release formulation comprises a reservoir system.

17. The method of claim 9 or 10 wherein said admixture further comprises an anti-inflammatory drug.

10 18. The method of claim 9 or 10 further comprising the steps of allowing growth of new cartilage tissue and surgically contouring the new cartilage surface.

19. A composition for intraarticular delivery of chondrogenic polypeptides, substantially as hereinbefore described with reference to any one of the examples.

15 20. Use of a pharmaceutically acceptable admixture consisting of FGF18 and hyaluronic acid for the manufacture of a medicament for the treatment of osteoarthritis in a mammal.

Dated 16 July, 2009
ZymoGenetics, Inc.

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

20

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> METHODS FOR ADMINISTERING FGF18

<130> 02-21PC

<150> 60/416,670

<151> 2002-10-07

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 917

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(621)

<400> 1

atg	tat	tca	gcg	ccc	tcc	gcc	tgc	act	tgc	ctg	tgt	tta	cac	ttc	ctg	48
Met	Tyr	Ser	Ala	Pro	Ser	Ala	Cys	Thr	Cys	Leu	Cys	Leu	His	Phe	Leu	
1				5					10					15		
ctg	ctg	tgc	ttc	cag	gta	cag	gtg	ctg	ggt	gcc	gag	gag	aac	gtg	gac	96
Leu	Leu	Cys	Phe	Gln	Val	Gln	Val	Leu	Val	Ala	Glu	Glu	Asn	Val	Asp	
			20					25					30			
ttc	cgc	atc	cac	gtg	gag	aac	cag	acg	cgg	gct	cgg	gac	gat	gtg	agc	144
Phe	Arg	Ile	His	Val	Glu	Asn	Gln	Thr	Arg	Ala	Arg	Asp	Asp	Val	Ser	
		35					40					45				
cgt	aag	cag	ctg	cgg	ctg	tac	cag	ctc	tac	agc	cgg	acc	agt	ggg	aaa	192
Arg	Lys	Gln	Leu	Arg	Leu	Tyr	Gln	Leu	Tyr	Ser	Arg	Thr	Ser	Gly	Lys	
	50					55					60					
cac	atc	cag	gtc	ctg	ggc	cgc	agg	atc	agt	gcc	cgc	ggc	gag	gat	ggg	240
His	Ile	Gln	Val	Leu	Gly	Arg	Arg	Ile	Ser	Ala	Arg	Gly	Glu	Asp	Gly	
	65				70					75					80	
gac	aag	tat	gcc	cag	ctc	cta	gtg	gag	aca	gac	acc	ttc	ggt	agt	caa	288
Asp	Lys	Tyr	Ala	Gln	Leu	Leu	Val	Glu	Thr	Asp	Thr	Phe	Gly	Ser	Gln	
				85					90					95		
gtc	cgg	atc	aag	ggc	aag	gag	acg	gaa	ttc	tac	ctg	tgc	atg	aac	cgc	336
Val	Arg	Ile	Lys	Gly	Lys	Glu	Thr	Glu	Phe	Tyr	Leu	Cys	Met	Asn	Arg	
			100					105					110			
aaa	ggc	aag	ctc	gtg	ggg	aag	ccc	gat	ggc	acc	agc	aag	gag	tgt	gtg	384
Lys	Gly	Lys	Leu	Val	Gly	Lys	Pro	Asp	Gly	Thr	Ser	Lys	Glu	Cys	Val	
		115					120					125				
ttc	atc	gag	aag	ggt	ctg	gag	aac	aac	tac	acg	gcc	ctg	atg	tcg	gct	432
Phe	Ile	Glu	Lys	Val	Leu	Glu	Asn	Asn	Tyr	Thr	Ala	Leu	Met	Ser	Ala	
		130				135					140					

```

aag tac tcc ggc tgg tac gtg ggc ttc acc aag aag ggg cgg ccg cgg 480
Lys Tyr Ser Gly Trp Tyr Val Gly Phe Thr Lys Lys Gly Arg Pro Arg
145                150                155                160

aag ggc ccc aag acc cgg gag aac cag cag gac gtg cat ttc atg aag 528
Lys Gly Pro Lys Thr Arg Glu Asn Gln Gln Asp Val His Phe Met Lys
                165                170                175

cgc tac ccc aag ggg cag ccg gag ctt cag aag ccc ttc aag tac acg 576
Arg Tyr Pro Lys Gly Gln Pro Glu Leu Gln Lys Pro Phe Lys Tyr Thr
                180                185                190

acg gtg acc aag agg tcc cgt cgg atc cgg ccc aca cac cct gcc 621
Thr Val Thr Lys Arg Ser Arg Ile Arg Pro Thr His Pro Ala
                195                200                205

taggccaccc cgccgcggcc ctcaggtcgc cctggccaca ctcacactcc cagaaaactg 681
catcagagga atatttttac atgaaaaata aggattttat tgttgacttg aaacccccga 741
tgacaaaaga ctcacgcaaa gggactgtag tcaaccacaca ggtgcttgtc tctctctagg 801
aacagacaac tctaaactcg tccccagagg aggacttgaa tgaggaaacc aacactttga 861
gaaaccaaag tcctttttcc caaaggttct gaaaaaaaaa aaaaaaaaaa ctcgag 917

```

```

<210> 2
<211> 207
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Tyr Ser Ala Pro Ser Ala Cys Thr Cys Leu Cys Leu His Phe Leu
 1          5          10
Leu Leu Cys Phe Gln Val Gln Val Leu Val Ala Glu Glu Asn Val Asp
 20          25          30
Phe Arg Ile His Val Glu Asn Gln Thr Arg Ala Arg Asp Asp Val Ser
 35          40          45
Arg Lys Gln Leu Arg Leu Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys
 50          55          60
His Ile Gln Val Leu Gly Arg Arg Ile Ser Ala Arg Gly Glu Asp Gly
 65          70          75
Asp Lys Tyr Ala Gln Leu Leu Val Glu Thr Asp Thr Phe Gly Ser Gln
 85          90          95
Val Arg Ile Lys Gly Lys Glu Thr Glu Phe Tyr Leu Cys Met Asn Arg
100          105          110
Lys Gly Lys Leu Val Gly Lys Pro Asp Gly Thr Ser Lys Glu Cys Val
115          120          125
Phe Ile Glu Lys Val Leu Glu Asn Asn Tyr Thr Ala Leu Met Ser Ala
130          135          140
Lys Tyr Ser Gly Trp Tyr Val Gly Phe Thr Lys Lys Gly Arg Pro Arg
145          150          155
Lys Gly Pro Lys Thr Arg Glu Asn Gln Gln Asp Val His Phe Met Lys
165          170          175
Arg Tyr Pro Lys Gly Gln Pro Glu Leu Gln Lys Pro Phe Lys Tyr Thr
180          185          190
Thr Val Thr Lys Arg Ser Arg Arg Ile Arg Pro Thr His Pro Ala
195          200          205

```

```

<210> 3
<211> 1023
<212> DNA
<213> Mus musculus

```

```

<220>

```

<221> CDS

<222> (1)...(624)

<400> 3

```

atg tat tca gcg ccc tcc gcc tgc act tgc ctg tgt tta cac ttt cta 48
Met Tyr Ser Ala Pro Ser Ala Cys Thr Cys Leu Cys Leu His Phe Leu
1 5 10 15

ctg ctg tgc ttc cag gtt cag gtg ttg gca gcc gag gag aat gtg gac 96
Leu Leu Cys Phe Gln Val Gln Val Leu Ala Ala Glu Glu Asn Val Asp
20 25 30

ttc cgc atc cac gtg gag aac cag acg cgg gct cga gat gat gtg agt 144
Phe Arg Ile His Val Glu Asn Gln Thr Arg Ala Arg Asp Asp Val Ser
35 40 45

cgg aag cag ctg cgc ttg tac cag ctc tat agc agg acc agt ggg aag 192
Arg Lys Gln Leu Arg Leu Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys
50 55 60

cac att caa gtc ctg ggc cgt agg atc agt gcc cgt ggc gag gac ggg 240
His Ile Gln Val Leu Gly Arg Arg Ile Ser Ala Arg Gly Glu Asp Gly
65 70 75 80

gac aag tat gcc cag ctc cta gtg gag aca gat acc ttc ggg agt caa 288
Asp Lys Tyr Ala Gln Leu Val Glu Thr Asp Thr Phe Gly Ser Gln
85 90 95

gtc cgg atc aag ggc aag gag aca gaa ttc tac ctg tgt atg aac cga 336
Val Arg Ile Lys Gly Lys Glu Thr Glu Phe Tyr Leu Cys Met Asn Arg
100 105 110

aaa ggc aag ctc gtg ggg aag cct gat ggt act agc aag gag tgc gtg 384
Lys Gly Lys Leu Val Gly Lys Pro Asp Gly Thr Ser Lys Glu Cys Val
115 120 125

ttc att gag aag gtt ctg gaa aac aac tac acg gcc ctg atg tct gcc 432
Phe Ile Glu Lys Val Leu Glu Asn Asn Tyr Thr Ala Leu Met Ser Ala
130 135 140

aag tac tct ggt tgg tat gtg ggc ttc acc aag aag ggg cgg cct cgc 480
Lys Tyr Ser Gly Trp Tyr Val Gly Phe Thr Lys Lys Gly Arg Pro Arg
145 150 155 160

aag ggt ccc aag acc cgc gag aac cag caa gat gta cac ttc atg aag 528
Lys Gly Pro Lys Thr Arg Glu Asn Gln Gln Asp Val His Phe Met Lys
165 170 175

cgt tac ccc aag gga cag gcc gag ctg cag aag ccc ttc aaa tac acc 576
Arg Tyr Pro Lys Gly Gln Ala Glu Leu Gln Lys Pro Phe Lys Tyr Thr
180 185 190

aca gtc acc aag cga tcc cgg cgg atc cgc ccc act cac ccc ggc tag 624
Thr Val Thr Lys Arg Ser Arg Arg Ile Arg Pro Thr His Pro Gly *
195 200 205

gtccggccac actcaccccc ccagagaact acatcagagg aatattttta catgaaaaat 684
aaggaagaat ctctatTTTT gtacattgtg tttaaaagaa gacaaaaact gaacctaaag 744
tcttggggagg agggggcgata ggattccact gttgacctga accccatgac aaaggactca 804
cacaaggga ccgctgtcaa cccacaggtg cttgcctctc tctaggagggt gacaattcaa 864
aactcatccc cagaggagga cttgaacgag gaaactgcga gaaaccaaaag tcctttcccc 924
ccaaggttc tgaagcaaa caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 984

```


aaaaaaaaaa aaaaaaaaaa gggcggccgc tctagagga

1023

<210> 4

<211> 207

<212> PRT

<213> Mus musculus

<400> 4

Met	Tyr	Ser	Ala	Pro	Ser	Ala	Cys	Thr	Cys	Leu	Cys	Leu	His	Phe	Leu
1				5					10					15	
Leu	Leu	Cys	Phe	Gln	Val	Gln	Val	Leu	Ala	Ala	Glu	Glu	Asn	Val	Asp
			20					25					30		
Phe	Arg	Ile	His	Val	Glu	Asn	Gln	Thr	Arg	Ala	Arg	Asp	Asp	Val	Ser
		35					40					45			
Arg	Lys	Gln	Leu	Arg	Leu	Tyr	Gln	Leu	Tyr	Ser	Arg	Thr	Ser	Gly	Lys
	50					55					60				
His	Ile	Gln	Val	Leu	Gly	Arg	Arg	Ile	Ser	Ala	Arg	Gly	Glu	Asp	Gly
65					70					75					80
Asp	Lys	Tyr	Ala	Gln	Leu	Leu	Val	Glu	Thr	Asp	Thr	Phe	Gly	Ser	Gln
				85					90					95	
Val	Arg	Ile	Lys	Gly	Lys	Glu	Thr	Glu	Phe	Tyr	Leu	Cys	Met	Asn	Arg
			100					105						110	
Lys	Gly	Lys	Leu	Val	Gly	Lys	Pro	Asp	Gly	Thr	Ser	Lys	Glu	Cys	Val
			115				120						125		
Phe	Ile	Glu	Lys	Val	Leu	Glu	Asn	Asn	Tyr	Thr	Ala	Leu	Met	Ser	Ala
							135					140			
Lys	Tyr	Ser	Gly	Trp	Tyr	Val	Gly	Phe	Thr	Lys	Lys	Gly	Arg	Pro	Arg
145					150					155					160
Lys	Gly	Pro	Lys	Thr	Arg	Glu	Asn	Gln	Gln	Asp	Val	His	Phe	Met	Lys
				165						170				175	
Arg	Tyr	Pro	Lys	Gly	Gln	Ala	Glu	Leu	Gln	Lys	Pro	Phe	Lys	Tyr	Thr
			180					185						190	
Thr	Val	Thr	Lys	Arg	Ser	Arg	Arg	Ile	Arg	Pro	Thr	His	Pro	Gly	
		195					200							205	